Tag:

Sanofi

Latest Headlines

Latest Headlines

Biotech R&D is changing. Don't get left behind

Over the last few years we've seen some big changes in the way some drugs are developed. What better time to host a new FierceBiotech executive panel discussion on current trends in late-stage development?

FDA approves Sanofi's Menactra as meningococcal booster

The new nod could boost sales of the French drugmaker's vaccine, a lift it could use after Menactra's top-line haul in 2013 sank to €424 million in a 21.5% slide.

Sanofi keeps the faith in MS and eyes a new dawn for Genzyme

Despite an FDA rejection and changing winds in the field of multiple sclerosis, Sanofi believes its Genzyme unit is on an upward trajectory, talking up potential deals and could-be blockbusters for its pricey acquisition.

Takeda on track for dengue vaccine nods in 2017-18

Sanofi's dengue vaccine isn't slated to hit the market until late next year, pending approval, but it already has some competition on the horizon. Takeda has its eye on nods in the U.S. and Europe for its own candidate by the 2017-18 fiscal year, it says.

UPDATED: Merck again shipping BCG cancer treatment but Sanofi still is not

When a shortage of BCG vaccine used to treat tuberculosis and bladder cancer developed two years ago because of serious problems at a Sanofi Pasteur plant, the FDA asked Merck to pick up the slack. But Merck has had supply issues that interrupted production that it is only now resolving.

Sanofi's latest gaming app invites kids on diabetes-fighting mission

When it comes to engaging patients and teaching them to manage their Type 1 diabetes, Sanofi is starting young. The French drugmaker last week rolled out a new app aimed at children, designed to help them share their knowledge about the disease.

It's megablockbuster halfsies for Sanofi, Amgen in next new cholesterol market

When is cholesterol fighting a game of six of one, half dozen of the other? Could be when the contest is between Amgen and its PCSK9 inhibitor evolocumab, and Sanofi and Regeneron's rival alirocumab. Despite some dramatic new data from the latter team--and a first-up filing with the FDA by Amgen--analysts figure on a dead heat once the drugs hit the market.

Sanofi posts positive PhIII dengue data with eye on global vaccine lead

Sanofi's eyeing the top spot in the world vaccines market, and new Phase III results for its dengue jab may just help it get there. The positive results bode well for the candidate's shot at an FDA nod, which could pad the French drugmaker's vaccines haul by more than $1.3 billion a year, analysts say.

What price for an oral Gaucher drug? $310,250, says Genzyme

Here's why Big Pharma wants to be in rare diseases--and why Sanofi made its $20.1 billion play for Genzyme.

Genzyme puts $310,250 price tag on new Gaucher-fighting pill

Here's why Big Pharma wants to be in rare diseases--and why Sanofi made its $20.1 billion play for Genzyme. The company has slapped a price tag on its new oral treatment for Gaucher disease, Cerdelga: $310,250 per year.